Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Once-weekly Supaglutide Versus Placebo in Patients With Type 2 Diabetes Suboptimally Controlled on Diet and Exercise: A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial

NCT04994288 is registered in ClinicalTrials.gov with Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. as lead sponsor.

NCT NCT04994288
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04994288 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Once-weekly Supaglutide Versus Placebo in Patients With Type 2 Diabetes Suboptimally Controlled on Diet and Exercise: A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial
Lead sponsor
Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
Phase
Phase 2/3
Overall status
Completed
Start date
August 3, 2021
Completion date
August 16, 2023
Enrollment
547 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

type2 diabetes